BC Extra | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said EVP and Chief Medical and Development Officer Adam Steensberg will become interim CEO on March 1. He will succeed Britt Meelby Jensen, who is leaving the company on Feb....
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
BC Week In Review | Jul 27, 2018
Company News

Nabriva acquires Zavante

Nabriva Therapeutics plc (NASDAQ:NBRV) acquired Zavante Therapeutics Inc. (San Diego, Calif.) for 8.2 million Nabriva shares, or $27.1 million based on the company’s close of $3.30 on July 24, before the acquisition was announced after...
BC Week In Review | Apr 7, 2017
Clinical News

Zolyd: Ph II/III ZEUS data

The double-blind, international Phase II/III ZEUS trial in 465 patients showed that thrice-daily 6 g IV Zolyd met the primary endpoint of non-inferiority to thrice-daily 4.5 g piperacillin/tazobactam in the proportion of patients who achieved...
BC Extra | Apr 6, 2017
Clinical News

Zavante's Zolyd meets in pivotal cUTI study

Zavante Therapeutics Inc. (San Diego, Calif.) said Zolyd fosfomycin (ZTI-01) met the primary endpoint in the Phase II/III ZEUS trial to treat complicated urinary tract infections (cUTIs). The company plans to submit an NDA to...
BC Week In Review | Jan 24, 2017
Clinical News

Fosfomycin: Ph II/III ZEUS ongoing

Zavante completed treatment of 465 patients in the double-blind, international Phase II/III ZEUS trial comparing 6 g IV ZTI-01 thrice daily vs. IV piperacillin/tazobactam thrice daily for 7-14 days. Zavante Therapeutics Inc , San Diego, Calif. ...
BC Week In Review | Apr 25, 2016
Clinical News

Fosfomycin: Pivotal trial started

Zavante began the double-blind, international pivotal ZEUS trial to compare IV ZTI-01 vs. piperacillin/tazobactam in 460 hospitalized adults with cUTIs, including acute pyelonephritis. Zavante Therapeutics Inc. , San Diego, Calif.   Product: Fosfomycin ( ZTI-01 )   Business:...
BC Extra | Apr 5, 2016
Financial News

Antibacterial play Entasis raises $50M series B

Entasis Therapeutics Inc. (Waltham, Mass.) raised $50 million in a series B round led by new investor Clarus Ventures. Frazier Healthcare Partners, Novo A/S (Hellerup, Denmark) and Eventide Funds also participated. Entasis' lead program is...
BioCentury | Apr 4, 2016
Finance

Frazier's GAIN

The benefits of the Generating Antibiotic Incentives Now Act, coupled with the ability to back repeat entrepreneurs, prompted Frazier Healthcare Partners to lead investments in two series A rounds for antibiotics companies in the span...
BC Week In Review | Apr 4, 2016
Financial News

Zavante completes venture financing

Zavante Therapeutics Inc. , San Diego, Calif.   Business: Infectious   Date completed: 2016-03-30   Type: Venture financing   Raised: $45 million   Investors: Frazier Healthcare; Longitude Capital Management; Aisling Capital   Note: The offering includes...
Items per page:
1 - 10 of 11
BC Extra | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said EVP and Chief Medical and Development Officer Adam Steensberg will become interim CEO on March 1. He will succeed Britt Meelby Jensen, who is leaving the company on Feb....
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
BC Week In Review | Jul 27, 2018
Company News

Nabriva acquires Zavante

Nabriva Therapeutics plc (NASDAQ:NBRV) acquired Zavante Therapeutics Inc. (San Diego, Calif.) for 8.2 million Nabriva shares, or $27.1 million based on the company’s close of $3.30 on July 24, before the acquisition was announced after...
BC Week In Review | Apr 7, 2017
Clinical News

Zolyd: Ph II/III ZEUS data

The double-blind, international Phase II/III ZEUS trial in 465 patients showed that thrice-daily 6 g IV Zolyd met the primary endpoint of non-inferiority to thrice-daily 4.5 g piperacillin/tazobactam in the proportion of patients who achieved...
BC Extra | Apr 6, 2017
Clinical News

Zavante's Zolyd meets in pivotal cUTI study

Zavante Therapeutics Inc. (San Diego, Calif.) said Zolyd fosfomycin (ZTI-01) met the primary endpoint in the Phase II/III ZEUS trial to treat complicated urinary tract infections (cUTIs). The company plans to submit an NDA to...
BC Week In Review | Jan 24, 2017
Clinical News

Fosfomycin: Ph II/III ZEUS ongoing

Zavante completed treatment of 465 patients in the double-blind, international Phase II/III ZEUS trial comparing 6 g IV ZTI-01 thrice daily vs. IV piperacillin/tazobactam thrice daily for 7-14 days. Zavante Therapeutics Inc , San Diego, Calif. ...
BC Week In Review | Apr 25, 2016
Clinical News

Fosfomycin: Pivotal trial started

Zavante began the double-blind, international pivotal ZEUS trial to compare IV ZTI-01 vs. piperacillin/tazobactam in 460 hospitalized adults with cUTIs, including acute pyelonephritis. Zavante Therapeutics Inc. , San Diego, Calif.   Product: Fosfomycin ( ZTI-01 )   Business:...
BC Extra | Apr 5, 2016
Financial News

Antibacterial play Entasis raises $50M series B

Entasis Therapeutics Inc. (Waltham, Mass.) raised $50 million in a series B round led by new investor Clarus Ventures. Frazier Healthcare Partners, Novo A/S (Hellerup, Denmark) and Eventide Funds also participated. Entasis' lead program is...
BioCentury | Apr 4, 2016
Finance

Frazier's GAIN

The benefits of the Generating Antibiotic Incentives Now Act, coupled with the ability to back repeat entrepreneurs, prompted Frazier Healthcare Partners to lead investments in two series A rounds for antibiotics companies in the span...
BC Week In Review | Apr 4, 2016
Financial News

Zavante completes venture financing

Zavante Therapeutics Inc. , San Diego, Calif.   Business: Infectious   Date completed: 2016-03-30   Type: Venture financing   Raised: $45 million   Investors: Frazier Healthcare; Longitude Capital Management; Aisling Capital   Note: The offering includes...
Items per page:
1 - 10 of 11